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Summary 5'-nucleotidase activity, arachidonate metabolism and adenosine uptake were measured in P388
murine leukaemia cells and in a subline resistant to doxorubicin. These membranes related activities were
found to be increased in the doxorubicin resistant cell line, compared to the drug sensitive cells. It is
suggested that these differences do not play a role in the mechanism of resistance to doxorubicin. Rather they
reflect alterations in plasma membrane composition and structure between these cell lines.
This study also suggests that the use of decreased 5'-nucleotidase activity as a marker of certain leukaemias
should be reviewed with caution. An increase in cell enzyme activity in treated patients may not necessarly
indicate a shift toward normal behaviour of these cells, but rather a selection of certain cell subpopulations.
Uusitalo & Karnovsky (1977) have shown that the
activity of 5'-nucleotidase of different populations
of mouse lymphocytes may vary considerably. Raz
et al. (1978) measured the activity of this enzyme in
Moloney virus-induced lymphoma, methylcholan-
thrane-induced lymphoma and their normal
parental mouse lymphocytes. They found a marked
reduction in the specific activity of 5'-nucleotidase
in the lymphoma cells compared to normal lympho-
cytes. Similar differences in 5'nucleotidase activity
were found by Petitou et al. (1978) between human
normal donors and leukaemic patients. They have
also found a marked decrease in the cell membrane
lipid structural order of leukaemic cells compared
to normal lymphocytes. These findings suggest a
possible relationship between the two phenomena.
We have recently reported that the membrane
lipid structural order of doxorubicin-resistant P388
cells is higher than that measured in the parent
doxorubicin-sensitive P388 cell line (Ramu et al.,
1983a). This change is apparently the result of the
difference in membrane lipid composition (Ramu et
al., 1983b). Therefore, we have studied whether the
increase in membrane lipid structural order, found
in doxorubicin-resistant P388 cells is also associated
with an increase in the cell 5'-nucleotidase activity.
As changes in cell membrane lipid composition
and structural order may affect cell membrane-
associated activities, we have also compared in
these cell lines the metabolism of arachidonate and
the uptake of adenosine.
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Materials and methods
P388 murine leukemia cells (Dawe & Potter, 1957)
and a subline resistant to doxorubicin (Johnson et
al., 1976) were grown in suspension culture in
RPMI 1640 medium (Grand Island Biological Co.,
Grand Island, N.Y.), supplemented with 10% heat-
inactivated foetal bovine serum (Grand Island
Biological Co.), 10MM 2-mercaptoethanol (Sigma
Chemical Co., St. Louis, Mo.), 50uml- penicillin
base and 50 ugml-' streptomycin base (both from
Grand Island Biological Co.). Cell densities were
measured using a Coulter Counter (ZB,; Coulter
Electronics Ltd., Harpenden, Herts, England). Cells
were transferred to fresh medium every 4 days to
sustain exponential growth. Initial cell densities
were 1iOcellsml-' and after 4 days, their density
reached 1-2 x 106cellsml-'. In all studies where
doxorubicin-sensitive and -resistant P388 cells were
compared, measurements were performed with cells
harvested on the fourth day ofgrowth.
The sensitivity of both cell lines to doxorubicin
was assessed as follows: cells were cultured in the
presence of various drug concentrations and the
slope of the log cell density versus time plot was
calculated by linear regression analysis. The growth
rate at each drug concentration was expressed as
the percentage of the control growth rate. Dose
effect curves were thus produced and were used to
determine the concentration of drug effective in
inhibiting the growth rate by 50% (ED50). The
doxorubicin ED50 for drug-sensitive and drug-
resistant P388 cells was 2 to 4 x 10-8 M and 1-
2 x 10-6 M respectively. No change in drug sensi-
tivity of either cell line was observed during 3 years
of continuous in vitro culture. Similarly, the sensi-
tivity of both cell lines to indomethacin and nitro-
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benzylthioinosine (both from Sigma Chemical Co.),
in the presence and absence of doxoribicin, was also
measured.
5'-nucleotidase assay
Cells were harvested by centrifugation (700g for
10min), washed x 3 in Tris-buffered saline (TBS,
Tris-buffer 10mM, pH 7.8, NaCl 0.9%) and
adjusted to 4-6 x 106cellsml-'. Enzyme activity
was assayed by a modification of a previously
described method (Reaman et al., 1979). The
reaction was carried out in a plastic tube (2040
Falcon, Div. Becton, Dickinson & Co., Oxnard,
Ca.), and the reaction mixture contained 10imol
3-glycerophosphate (Sigma Chemical Co.), 10 umol
MgCl2 and 105 cells. The mixture was preincubated
for 15min at 37°C and then substrate was added:
Adenosine 5'-monophosphate (AMP, Sigma
Chemical Co.) 10nmol with (U-14C)Adenosine 5'-
monophosphate (14C-AMP, Amersham Searle, Park
Ridge, Ill.). The volume of the reaction mixture was
adjusted to 0.5ml, mixed thoroughly, and the tubes
were then incubated at 37°C for 30min. The
reaction was stopped by adding 100 1l of 0.25M
ZnSO4. Unreacted AMP was precipitated by
adding 100I 1 of 0.25M Ba(OH)2. The final volume
was adjusted to 1.0ml and the tubes kept cold for
h and then centrifuged at 1200g for 15min.
Supernatant (0.5ml) was aspirated into a vial
containing 5ml scintillation fluid (ScintiVerse,
Fisher Scientific Instruments, Pittsburgh, Pa.) and
counted in a scintillation counter. Controls
consisted of samples which contained neither cells
nor ZnSO4 and Ba(OH)2, samples with ZnSO4 and
Ba(OH)2, and samples with cells held in boiling
water for 10min. Normally between 5 and 20% of
the AMP substrate was hydrolysed and under these
conditions, >95% of the cells were viable.
Substrate hydrolysis was directly proportional to
the cell concentration. Radioactivity present in the
supernatant is proportional to the 5'nucleotidase
activity of the sample. P-glycerophosphate was
included in the assay to insure its specificity for
5'nucleotidase activity (Belfield & Goldberg, 1968).
Assayfor arachidonate metabolites
Washed cells from both lines were incubated in
RPMI 1640 medium (without serum) at 37°C. Cell
density was 2 x 106 ml-1. After 3h, the samples
were centrifuged at 700g for 10min and the super-
natants were separated and frozen at -20°C until
assayed. Prostaglandins in the supernatants were
determined by direct radioimmunoassay
(Granstrom & Kindhal, 1976). The radiolabelled
prostaglandins and the antibodies for 6-keto-PGF1I
and for thromboxane B2 were purchased from New
England Nuclear (Boston, Ma). The antibody for
PGE2 was purchased from Accurate Chemicals and
Scientific Co., (New York, NY).
Adenosine uptake
Uptake of [2-3H] Adenosine (Amersham Searle)
was determined in both cell lines. Cell suspensions
containing 5 x 104 cells in 0.25ml medium were
incubated on a shaker at 37°C. After 10min of
preincubation [3H]-adenosine was added. The
incubation was terminated after 15min by centri-
fugation for 2min in a microfuge (model 152
Beckman Instruments, Inc., Palo Alto, Ca.). The
cells were washed x 3 with cold PBS and then
solubilized in 0.1 ml of detergent (Nonidet P40,
Shell Oil Co., UK). Radioactivity was determined
after the addition of 5ml scintillation fluid. In some
experiments, an inhibitor of adenosine transport: p-
nitrobenzyladenosine (PBTA, obtained from the
Chemical Synthesis branch, National Cancer
Institute, Bethesda, Md) was added at a concen-
tration of 10-6M.
Results
5'-nucleotidase activity
The activity of 5'nucleotidase did not change in
cells from either line as the cells were passaged in
vitro, between transfers 23 and 90 (Table I). The
activity of this enzyme was 10 times higher in
doxorubicin resistant cells than in the drug sensitive
Table I 5'-nucleotidase activity in doxorubicin-sensitive and -resistant
P388 cells
nmol AMP hydrolyzed by 106cellsh-
mean + s.d. (no. experiments)
control +1% non idet P40
Doxorubicin-sensitive
P388 cells 1.1I+0.58 (n = 12) 3.51 + 1.49 (n=4)
Doxorubicin-resistant
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P388 cells. Cells that were incubated for 24h in
media containing 20,uM of adenosine or AMP,
showed the same level of enzyme activity as
untreated cells. These levels of enzyme activity were
also found in cells of both lines freshly collected
from ascites fluid withdrawn from tumour-bearing
CDF1 mice.
In the presence of the detergent Nonident P40
(1%) the enzyme activity increased 3-fold in both
cell lines and the relative difference in activity
between the lines was maintained.
Metabolism ofarachidonate
The spontaneous release of PGE2, 6-keto-PGF1a
and thromboxane B2 from drug sensitive and
resistant cells is shown in Table II. The doxorubicin
resistant P388 cells exhibited higher release of all
the arachidonate metabolites assayed. The most
conspicious difference observed was in the release of
PGE2 (6-fold).
In order to examine a possible correlation
between inhibition of growth by doxorubicin and
the metabolism of arachidonic acid, cells of both
lines were exposed to the drug in concentrations
which inhibit the cell growth rate by 50%. Under
these conditions, the release of PGE2 from drug-
sensitive cells was reduced to 52.2% of that
obtained from these cells incubated without doxo-
rubicin. In doxorubicin-resistant cells, the drug
inhibited the release of PGE2 by only 18.5%.
Indomethacin, at the highest non-inhibitory
concentration (3 x 10- M), did not affect the sensi-
tivity of either cell line to doxorubicin.
Adenosine uptake
The initial rate of adenosine uptake by doxo-
rubicin-sensitive and -resistant P388 cells, is shown
in Table III. This uptake was largely suppressed by
p-nitrobenzyladenosine, a blocker of adenosine
transport. The uptake of adenosine in doxorubicin-
resistant cells is considerably higher than that
measured in drug-sensitive P388 cells.
Nitrobenzylthioinosine, another blocker of
adenosine transport (Lauzon & Paterson, 1977), at
the highest non-inhibitory concentration
(3 x 10-6M), did not affect the sensitivity of either
cell line to doxorubicin.
Discussion
The present experiments have shown that the
parent P388 cell line, a methylcholanthrene-induced
lymphoid neoplasm in DBA/2 mouse (Dawe &
Potter, 1957), have measurable 5'nucleotidase
activity. This activity is much lower than that
measured in normal DBA/2 mouse lymphocytes
(Uusitalo & Karnovsky, 1977). The activity of 5'-
nucleotidase measured in the doxorubicin-resistant
Table II The spontaneous release of arachidonate metabolites from doxo-
rubicin-sensitive and -resistant P388 cells
pg ofmetabolite 106 cells 3h-
mean + s.d. (4 experiments)
PGE2 6-keto-PGF1,, thromboxane B2
Doxorubicin-sensitive
P388 cells 46.1 + 15.8 100+ 10.2 2.2+0.3
Doxorubicin-resistant
P388 cells 296.2+22.8 200+21.4 4.6+0.4
Table III Adenosine uptake by doxorubicin-sensitive and -resistant
P388 cells
pmol adenosine 106 cells h-
mean + s.d. (n=3)
control +nitrobenzyladenosine
Doxorubicin-sensitive
P388 cells 4.56+0.80 1.21 +0.04
Doxorubicin-resistant
P388 cells 14.84+2.68 1.28 +0.36450 A. RAMU et al.
subline, selected by the drug from the parent P388
cell population, was significantly higher than that
measured in the parent cell line and was not
significantly different from the activity reported for
normal DBA/2 mouse lymphocytes.
The activity of this enzyme in either cell line was
not affected by prior incubation of the cells in the
presence of adenosine or AMP.
The increased activity of 5'-nucleotidase
measured in doxorubicin-resistant cells, compared
to drug-sensitive cells, may represent an increase in
the amount of enzyme protein or an increase in its
specific activity as a result of some change in the
protein structure or its relation to other
constituents of the cell membrane. After solubili-
zation with a detergent, an increase in 5'-nucleo-
tidase activity was measured. However, similar
increase in enzyme activity was obtained in both
cell lines. A detergent may on one hand increase
membrane-bound enzyme activity by increasing its
exposure (Solomonson et al., 1976) and on the
other hand, may disrupt some enhancing effect of
the lipid/protein interaction (Englehard et al.,
1976). Therefore this negative result does not
support either possibility.
Although this study gives further support for the
suggested relationship between the level of activity
of 5'-nucleotidase, a membrane-bound enzyme, and
the degree of structural order of the cell membrane
lipid domain, the explanation for this relationship
remains obscure.
The activity of 5'nucleotidase measured in human
T- and B-lymphoma cell lines (Carson et al., 1979)
was much lower than that reported for the corres-
ponding normal human T- and B-lymphocytes
(Thompson et al., 1979; Rowe et al., 1979). It was
suggested that the activity level of this enzyme is
related to the degree of cell maturity (Poplack et
al., 1981). Decreased 5'-nucleotidase activity was
reported in most chronic lymphatic leukaemias
(Lopez et al., 1973; Marique & Hildebrand, 1973;
Quagliata et al., 1974; Kramers et al., 1976), in
lymphocytes of immunodeficient patients with
hypogammaglobulinemia (Johnson et al., 1977;
Edwards et al., 1978; Webster et al., 1978), T cell
lymphoblastic leukaemias (Reaman et al., 1979) and
B cell acute lymphoblastic leukaemias (Reaman et
al., 1981). It was suggested that the activity of this
enzyme may be used as a new biological marker of
certain diseases (Koya et al., 1981). Our data
clearly point toward the possibility that following
drug treatment and the emergence of drug-resistant
cell populations, the activity of 5'-nucleotidase in
the remaining tumour cells may change
considerably and an increase in the enzyme activity
in the remaining cells may not necessarily indicate a
shift toward higher differentiation.
Doxorubicin-resistant P388 cells release more
prostaglandin PGE2, thromboxane and prostacyclin
than drug-sensitive P388 cells. The differences in
arachidonate metabolism may reflect change in the
availability of arachidonic acid in these cells as a
part of the changes in cell lipid composition (Ramu
et al., 1983b). However, in preliminary experiments
where arachidonic acid was added in excess to the
incubation medium, the differences in arachidonate
metabolism were maintained. This indicates that the
change in arachidonate metabolism is caused by
changes in the activity of certain enzymes involved
in arachidonate metabolism rather than a difference
in the availability of arachidonic acid.
At equicytostatic concentrations of doxorubicin
(ED50), the release of PGE2 from drug-resistant
P388 cells was significantly less influenced by the
presence of doxorubicin than its release from drug-
sensitive cells. Therefore, we suggest that the
inhibition of release of PGE2 by the drug is
unrelated to its cytostatic effect. Furthermore as
indomethacin did not change the sensitivity of
either cell line to doxorubicin, we suggest that the
increase in arachidonate metabolism is not the
cause of doxorubicin resistance but rather reflects
changes in the membrane structure of these cells.
Changes in other membrane related activities were
found in drug resistant cells as: glycosidase
(Bosmann & Kessel, 1970), membrane glycoproteins
(Beck et al., 1979), high macromolecular lipid
(Taylor et al., 1981) and carrier-mediated uptake of
methotrexate (Kessel et al., 1965; Herman et al.,
1979). In the present study we have also noted that
these cell lines differ in another carrier-mediated
uptake system of the cell membrane, namely the
uptake of adenosine. The rate of adenosine
transport was significantly higher in doxorubicin-
resistant cells than in drug-sensitive cells. In both
cell lines the uptake could be blocked by a specific
adenoside transport blocker, nitrobenzyladenosine.
The finding that nitrobenzylthioinosine, another
potent inhibitor of nucleosine transport (Lauzon et
al., 1977), did not change the sensitivity of either
cell line to doxorubucin, suggests that the increase
in adenosine uptakes is not the cause of drug
resistance, but rather another reflection of the
change in membrane structure.5'-NUCLEOTIDASE AND DOXORUBICIN RESISTANCE 451
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